Jack Elands, PhD

Chief Executive Officer


Previous to BliNK Biomedical, Jack Elands was CEO of Amakem Therapeutics, a company that he cofounded in 2010. Jack was CEO of Vitec, a specialty biochemical company focused on antimicrobial surface chemistries and products, CBO of Silicos, an informatics platform-based biotechnology company and the VP of Business Development at Sidec AB, a Swedish company focused on the discovery and development of protein based drugs. Jack started his pharmaceutical career at Marion Merrell Dow (later HMR and Aventis, now Sanofi) where he was involved with the development of drugs such as terfenadine, fexofenadine and dolasetron. He has published extensively and has contributed to several patents. He received his undergraduate in medical biology from University of Utrecht in 1985. Jack was awarded his doctorate in Neuropharmacology from the Rudolf Magnus Institute at University of Utrecht in 1989.